Ovarian Cancer: Symptoms, Causes, Testing, and Treatment

Ovarian cancer symptoms are easy to miss, which is one reason this disease is often found at a later stage. Many early signs, such as bloating, pelvic pressure, and feeling full quickly, look like everyday digestive complaints, so they can go unrecognized for weeks or months. Understanding what to watch for, and which tests actually help, can support an earlier conversation with your doctor. In this article you will learn what ovarian cancer is and its main types, the symptoms and risk factors that matter, why a Pap smear does not detect it, which tests doctors use, whether screening exists for average-risk women, how genetic testing fits in, and how diagnosis and treatment usually work.

What ovarian cancer is, and its main types

Ovarian cancer is a malignant tumor that forms in the tissues of an ovary, one of the two female reproductive glands that make eggs and hormones. According to the National Cancer Institute, fallopian tube cancer and primary peritoneal cancer form in closely related tissue and are treated in the same way, so doctors often group them together.

There are several types. The most common by far is epithelial ovarian cancer, which begins in the cells covering the surface of the ovary. Rarer forms include germ cell tumors, which start in the egg-producing cells and tend to affect younger women, and stromal tumors, which arise in the hormone-producing connective tissue. A small number of tumors are classed as borderline, or low malignant potential, meaning they grow more slowly and behave less aggressively. The type and stage shape how the disease is managed.

Why it is often diagnosed late

The ovaries sit deep in the pelvis, and early tumors rarely cause obvious problems. As MedlinePlus notes, ovarian cancer may not cause early signs, and by the time symptoms appear the disease is often advanced. This biology, rather than any failing on the part of the patient, explains why awareness of subtle, persistent symptoms matters so much.

Ovarian cancer symptoms to watch for

The most commonly reported ovarian cancer symptoms are not dramatic, which is exactly why they deserve attention when they are new and persistent. The Centers for Disease Control and Prevention lists the following signs and symptoms:

• Bloating, or a feeling of pressure or swelling in the abdomen or pelvis.
• Pelvic or abdominal pain, and sometimes back pain.
• Feeling full too quickly, or difficulty eating (early satiety).
• A change in bathroom habits, such as a more frequent or urgent need to urinate, or constipation.
• Vaginal bleeding that is not normal for you, particularly after menopause.

The key is the pattern, not any single episode. Bloating after a large meal is ordinary; bloating that is new, does not go away, and occurs almost daily is worth checking. The CDC advises that if you have unusual vaginal bleeding you should see a doctor right away, and if you have any of the other symptoms for two weeks or longer and they are not normal for you, you should see a doctor. These symptoms are far more often caused by something benign, but only a clinician can sort that out.

Syyt ja riskitekijät

Ovarian cancer develops when genetic changes cause cells in or near the ovary to grow out of control. In most cases the exact trigger for those changes is unknown, and many women who develop the disease have no clear risk factor. That said, several factors are linked to a higher chance, and knowing them helps you and your doctor judge your personal situation.

According to MedlinePlus and the CDC, the recognized risk factors include:

• Older age, especially after menopause.
• A family history of ovarian cancer in a mother, sister, grandmother, or aunt.
• Inherited changes in the BRCA1 or BRCA2 genes, or conditions such as Lynch syndrome.
• Endometriosis.
• Never having been pregnant, or starting periods early and reaching menopause late.
• Use of menopausal hormone therapy, obesity, and certain reproductive factors.

Some factors point the other way and are associated with lower risk, including pregnancy, breastfeeding, and the past use of oral contraceptives. None of this means a woman with risk factors will develop the disease, or that a woman without them is fully protected; risk is about probability, not certainty.

The Pap smear myth, and what actually tests for ovarian cancer

One of the most common and important misunderstandings is the belief that a routine Pap smear can find ovarian cancer. It cannot. The CDC states plainly that the Pap test does not screen for ovarian cancer. A Pap smear samples cells from the cervix to look for cervical changes linked to HPV, and it is excellent for that purpose, but it does not examine the ovaries. If you want to understand what that cervical test does cover, our team explains the meaning of a normal Pap result with a positive HPV test, and a separate guide details the prevention and screening of kohdunkaulan syöpä.

When a woman has symptoms or a known high risk, doctors instead use a focused work-up. The CDC notes that a clinician may recommend a rectovaginal pelvic exam, a transvaginal ultrasound, or a CA-125 blood test, and that these can sometimes help find or rule out ovarian cancer. Each tool plays a different role:

• Pelvic exam: a physical examination that lets the doctor feel for masses or tenderness in the pelvis.
• Transvaginal ultrasound: an imaging test using a probe in the vagina to look closely at the ovaries and detect cysts or masses, and to describe their size and appearance.
• CA-125 blood test: a measure of a protein that can be raised in ovarian cancer but also rises in many benign conditions.
• HE4 and the ROMA score: additional blood markers. HE4 (human epididymis protein 4) is combined with CA-125 and menopausal status in the Risk of Ovarian Malignancy Algorithm to better estimate the chance that a pelvic mass is malignant.

It is essential to read these tests the right way. A blood marker supports a clinical picture; it does not, by itself, confirm or exclude cancer. CA-125 can be normal in roughly one in five early ovarian cancers, and it rises in conditions such as menstruation, endometriosis, fibroids, and ovarian cysts. To see how a clinician weighs a result, our team explains how to read a CA-125 blood test result, and a broader guide places this in the wider family of tumor markers and their limits. Because a transvaginal ultrasound is also the main way doctors assess a mass, you may find it useful to understand how ovarian cyst size and appearance are interpreted.

Is there a screening test for ovarian cancer?

For women at average risk who have no symptoms, the honest answer is no. The CDC is unambiguous: there is no reliable way to screen for ovarian cancer in women who do not have symptoms. Large studies have tested combinations of CA-125 and ultrasound in the general population and have not shown that they save lives; instead, they generate many false alarms, leading to anxiety and to surgery that turns out to be unnecessary. Screening, which looks for disease before symptoms appear, is different from diagnostic testing, which investigates symptoms that are already present.

This is why the emphasis for most women falls on knowing their body and acting on persistent changes, rather than on routine blood tests or scans. Women at high risk, for example because of a known BRCA mutation or a strong family history, are a separate group; they may be offered surveillance or risk-reducing options, but this is decided individually with a specialist.

Genetic testing and BRCA1/2

A meaningful share of ovarian cancers have a hereditary component. Inherited changes in the BRCA1 and BRCA2 genes, which normally help repair DNA, raise the lifetime risk of ovarian and breast cancer, and Lynch syndrome raises it too. Because the same genes are central to breast cancer risk, our guide on breast cancer and BRCA-related risk gives helpful background.

MedlinePlus notes that a provider may suggest genetic testing to look for the gene changes that increase risk, and that knowing whether a change is present can help guide a treatment plan. Genetic counseling usually comes first, so that a woman understands what a result would mean for her and for her relatives. In certain germ cell tumors, doctors may also check markers such as alfafetoproteiini (AFP) as part of the assessment, since these tumors can produce it.

Diagnosis and staging basics

Reaching a diagnosis usually combines several steps. As MedlinePlus describes, a clinician asks about your medical and family history, performs a physical and pelvic exam, often arranges imaging such as a transvaginal ultrasound, and may order blood tests including CA-125. These point toward or away from cancer, but they do not settle the question.

The only way to know for certain is to examine tissue. MedlinePlus explains that a biopsy, typically taken during surgery to remove the tumor, is usually required to confirm ovarian cancer. During that surgery the team also determines the stage, meaning how far the disease has spread, from confined to the ovaries through to involvement of the abdomen or beyond. Staging guides treatment and is established by the surgical and pathology findings rather than by a blood marker.

Treatment overview

Treatment is tailored to the type and stage of the cancer and to the individual, and it is delivered by a specialist team. According to MedlinePlus and the National Cancer Institute, the main approaches are:

• Surgery to remove as much of the cancer as possible, which also provides the tissue needed for diagnosis and staging.
• Chemotherapy, often used after surgery, and sometimes before it to shrink a tumor.
• Targeted therapy, which uses drugs designed to attack specific features of cancer cells with less harm to healthy ones. This category includes PARP inhibitors, discussed below, which are used in selected patients, particularly those with BRCA mutations or other markers of homologous recombination deficiency.

Outcomes vary widely depending on type, stage, and individual factors, and this article does not offer any prognosis. The purpose here is to explain the options so that a conversation with an oncologist is easier to follow. Decisions about treatment always belong with the medical team.

Milloin mennä lääkäriin

You do not need to wait for certainty to seek advice. Following CDC guidance, see a doctor right away if you have unusual vaginal bleeding, especially after menopause. For the other symptoms, such as persistent bloating, pelvic or abdominal pain, feeling full quickly, or new urinary urgency, see a doctor if they last two weeks or longer and are not normal for you. Bring a short note of when the symptoms started and how often they occur; that pattern is exactly what a clinician needs. The likeliest explanation is something benign, but getting it checked is the sensible step.

Uusimmat tieteelliset edistysaskeleet

Research is moving quickly, especially around earlier detection and more personalized treatment. The summaries below describe the type and scale of the evidence and, importantly, note where findings are still preliminary. None of these advances has yet produced a proven screening test for average-risk, symptom-free women. Based on articles retrieved from PubMed:

• A 2025 comprehensive review of early diagnosis (Hong and Ding, Diagnostics) concludes that current tools, including transvaginal ultrasound, CA-125, and HE4, have limited ability to catch early-stage disease, and that emerging approaches such as liquid biopsy, multi-omics, and artificial intelligence may help in the future but still require large-scale validation (DOI-koodi).
• A 2025 review of screening guidelines (Chiu and colleagues, RoFo) reports that major professional societies do not recommend routine population-based screening for ovarian cancer, because available methods produce too many false positives and miss too many early cancers; newer methods are promising but unproven for baseline-risk populations (DOI-koodi).
• An exploratory 2024 study (Li and colleagues, Cell Reports Medicine) used an artificial-intelligence model applied to cell-free DNA methylation markers in blood and reported high accuracy in distinguishing early epithelial ovarian cancer from healthy controls. This is an early-stage, proof-of-concept result that needs prospective testing in real-world screening settings (DOI-koodi).
• On treatment, a 2024 systematic review and meta-analysis of 16 randomized trials (Baradacs and colleagues, Journal of Ovarian Research) found that PARP inhibitors used as maintenance therapy lengthened progression-free survival in newly diagnosed and recurrent ovarian cancer, with the largest benefit in women with BRCA mutations, and with manageable side effects (DOI-koodi).
• A 2025 network meta-analysis of six randomized trials (Ji and colleagues, Journal of Ovarian Research) compared PARP inhibitors such as olaparib and niraparib as maintenance therapy in platinum-sensitive recurrent disease, finding consistent improvements in progression-free survival across BRCA and homologous-recombination-deficient subgroups (DOI-koodi).

Recruiting clinical trials reflect these themes. ClinicalTrials.gov lists studies evaluating multi-marker and biomarker panels for earlier ovarian cancer detection, such as the EARLY biomarker panel study (NCT07491081) and a large multi-cancer detection screening study, the Vanguard Study (NCT06995898) sponsored by the National Cancer Institute. These are investigational; their value will only be known once results are published.

Sanasto

Usein kysytyt kysymykset

Does a Pap smear detect ovarian cancer?

No. The CDC is explicit that the Pap test does not screen for ovarian cancer. A Pap smear collects cells from the cervix to look for changes linked to HPV that can lead to cervical cancer. It does not look at the ovaries and cannot find an ovarian tumor. If you have symptoms such as persistent bloating or pelvic pain, a normal Pap smear should not be reassuring about your ovaries; speak with your doctor about whether other tests, such as a pelvic exam, transvaginal ultrasound, or CA-125, are appropriate for your situation.

Can a blood test or a full blood count detect ovarian cancer?

Not on its own, and a standard complete blood count is not designed to find it. The blood test most associated with ovarian cancer is CA-125, sometimes paired with HE4 in the ROMA score, but these support a diagnosis rather than confirm one. CA-125 can be normal in early disease and raised by benign conditions such as endometriosis or fibroids. Only examining tissue, usually through surgery and biopsy, confirms ovarian cancer. If you want help reading these values, our guide explains how to interpret a blood test report.

How can I get tested for ovarian cancer?

Start by talking with your doctor about your symptoms and any family history. There is no reliable test to screen women without symptoms, so testing is guided by your situation. If indicated, a clinician may perform a pelvic exam, arrange a transvaginal ultrasound, and order a CA-125 blood test, sometimes with HE4. These help find or rule out a problem and decide whether a referral to a gynecologic specialist is needed. A definitive answer requires tissue examination, which is done if imaging and exam raise concern.

Is ovarian cancer hereditary or genetic?

It can be. Most ovarian cancers arise from genetic changes that happen during a person’s lifetime, but some are inherited. As MedlinePlus explains, inherited changes in BRCA1 and BRCA2, and conditions such as Lynch syndrome, raise the risk, and a family history of ovarian cancer is an important factor. If your family history suggests inherited risk, your doctor may recommend genetic counseling and testing. Knowing whether a gene change is present can inform both your own care and your relatives’ decisions.

Can an ultrasound detect ovarian cancer?

A transvaginal ultrasound can detect an ovarian cyst or mass and describe its size and appearance, which helps a doctor judge how concerning it is. However, ultrasound alone cannot prove that a mass is cancer. Some benign cysts look complex, and some cancers can be hard to characterize. That is why ultrasound is combined with a pelvic exam, blood markers such as CA-125, and, when needed, surgery and biopsy. Ultrasound is a valuable first imaging step, not a final diagnosis.

What are the early warning signs I should not ignore?

Pay attention to symptoms that are new, persistent, and frequent rather than occasional. According to the CDC, these include bloating, pelvic or abdominal pain, feeling full quickly or trouble eating, and urinary urgency or frequency. Unusual vaginal bleeding, especially after menopause, should prompt a visit right away. For the other symptoms, see a doctor if they last two weeks or longer and are not normal for you. They are usually caused by something benign, but checking is the right move.

Lähteet

• National Cancer Institute (NIH) — Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
• Centers for Disease Control and Prevention — Ovarian Cancer
• MedlinePlus (NIH, National Library of Medicine) — Ovarian Cancer
• Hong and Ding, 2025, Diagnostics — Early Diagnosis of Ovarian Cancer (review)
• Chiu and colleagues, 2025, RoFo — Ovarian Cancer Screening: Recommendations and Future Prospects (review)
• Li and colleagues, 2024, Cell Reports Medicine — AI-based cfDNA methylation for early detection
• Baradacs and colleagues, 2024, Journal of Ovarian Research — PARP inhibitors meta-analysis
• Ji and colleagues, 2025, Journal of Ovarian Research — PARP inhibitor network meta-analysis

Lisälukemista

• CA-125: a guide to interpreting this blood marker
• Tumor markers explained: what they measure and their limits
• Ovarian cyst size: causes, symptoms, and risks
• Rintasyöpä: sairauden ymmärtäminen ja ehkäisy
• Verikokeen tulosten lukeminen

Ymmärrä laboratoriotuloksiasi tekoälyn DiagMen avulla

Tulkitse tuloksesi muutamassa minuutissa

Seeing values such as CA-125, HE4, a complete blood count, or other tumor markers on a report can be confusing, especially next to unfamiliar reference ranges. AI DiagMe reads your lab results and explains, in plain language, what each value means and which ones are worth raising with your doctor. It is built to help you understand your results, not to diagnose you or replace medical advice. Walk into your next appointment with clearer questions and more confidence.